Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of RANKL Inhibition on Healing of Bone Erosion in Rheumatoid Arthritis Using HR-pQCT

NCT03239080 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.

NCT NCT03239080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03239080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of RANKL Inhibition on Healing of Bone Erosion in Rheumatoid Arthritis Using HR-pQCT
Lead sponsor
Chinese University of Hong Kong
Phase
Phase 2
Overall status
Completed
Start date
June 19, 2017
Completion date
May 24, 2020
Enrollment
110 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis